Source Bioscience Share Discussion Threads

[garbil] 22/3/2012 09:12

hastings - 22 Mar'12 - 07:10 - 1791 of 1792


Thanks for that, hastings. Good to hear.

Do you by any chance have a link to the note?

TIA !

[buywell2] 22/3/2012 08:20

That is good hastings , but I hope for an update for better soon

Meantime , my number 1 choice has published it's finals today

Cyprotex (CRX) should hit the advfn riser board today I would have thought



The share price has the potential to now be a 6 bagger in just over a YEAR

Thus far the chart below has been SPOT ON

An INCREASE in turnover to £10m is expected for 2012 ie £2m or 25%

Could Cyprotex operating on a margin of 84% add £1.6m to their 2011 profits ?

This would mean OVER £2.4m profit for 2012

or

A forward P/E of just over 3 at the opening share price of 4.25p

Which would indicate that based upon a LOW forward P/E for a GROWTH company of say 20 ..... the share price could go up

BY A FACTOR OF 6


Cyprotex forecasts

[hastings] 22/3/2012 07:10

The new Broker note is out as of yesterday and well worth the wait. Pre tax profits of £1m for this year rising to £1.5m next year and EPS of 0.8p that puts SBS on a forward PER (next year) of only 9. For a company in growth mode who beyond that point will be highly cash generative it is a very cheap looking share. Sure things can go pear shaped, but it looks very much like the legacy of the past is beyond the company, onwards and upwards.

[hastings] 21/3/2012 12:45

Well good luck to Mr ifa and his 21% profit, but i would hope to make much more than that. However, SBS is not for the short term, indeed if it delivers a £1m profit for this year, i would say the real value here will be another three or four years away. The board is doing a damn good job here with some decent bolt-on acquisitions along with steady organic growth.

[buywell2] 21/3/2012 10:32

If SBS don't hit £1m profit in 2012 I will be very disappointed

At current share price ..... SBS is a target for preditors

One has to be exposed in order to get gobbled up

[bobby.ifa] 21/3/2012 10:17

Glad I sold up on Mondaty, made 21% on my switch into Quadrise & second on the risers board today. I'll join wilkie if these fall back sub 7p.

[wilkie_hk] 21/3/2012 10:14

IMO the close watchers and holders will see these results as decent progress on the way to ultimately posting pre-tax profits over the £1M mark and then moving on from there (hopefully this will be 2012 annuals). However, I can't see many outsiders being drawn in by the headline figures. Consequently, I see sideways movement in the share price to the interims, possibly in the 6-8p range. If we see 6p, I will likely top up.

[buywell2] 21/3/2012 08:03

Like I said in a previous post , £17m turnover was hoped for so there was a shortfall of circa £1.8m which was most likely caused by PharmaBiotech contracts not being taken up due to clients not getting patients signed up for presumably Phase 3 trials.

This work looks like it has rolled over and could now ADD to turnover in 2012
'we have a pipeline of contracts for clinical trial support and genomic services worth in excess of £2.0 million between 2012 and 2015.'

13% increase is good .... if £17m turnover had been hit then we would have been looking at an increase in turnover of 26%

My number 1 choice Cyprotex (CRX) reports their finals tommorrow

Turnover should be OVER 30% higher ... hence it's top rating

[hastings] 20/3/2012 21:42

Ken, the shares have put in a great performance over the last few months, pause for your breath old chap, a second wind and all that!

[peterz] 20/3/2012 19:59

We had better take a look then!

[bobby.ifa] 20/3/2012 18:23

I was out at 8.20, city do not like these lot. Invested proceeds in Quadrise fuels & it bounced perfectly. They've results out on Monday I hope.

[kenbachelor] 20/3/2012 17:25

Hastings - They may not be a bad set of results, but they haven't done much for the share price!

[hastings] 20/3/2012 12:58

Having had a little more time to run over things, i feel these are indeed a solid set of figures. SBS has,surely turned the corner and is very much on a growth path and given the economic woes the numbers are sound. I realise that some were perhaps hoping for more, but given the recent purchase and acquisitions made i think SBS has made damn good progress.
Profits are going to increase. (a new Broker note soon, will i am sure echo that) while the loan will be cleared in a relativley short time, leaving the company in a decent position. The shares are unlikley imo to move much in the short term, indeed we may come off a bit as some who are not prepared to wait offload. That could pave the way for those with a longer term horizon.

[garbil] 20/3/2012 11:06

More on GenomeCube worth highlighting:


In June 2011 we launched GenomeCube which represented Phase II of the
improvement programme to our LifeSciences e-commerce solution. GenomeCube is
our proprietary search engine, database and bioinformatics tool enabling
researchers access to the world's largest clone and antibody portfolio which
extends to over 20 million individual products. Following the launch of
GenomeCube activity across our e-commerce platform has increased significantly;
the number of visits to the website is up over 80% and the number of on-line
orders placed has increased by more than 50%.

Phase III of the project is currently underway which will further enhance the
functionality of GenomeCube®, enabling the platform to be rolled out across our
distributor network. This will accelerate the globalisation of our products
business and allow our international distributors, and customers, access to the
majority of our product portfolio utilising the power of GenomeCube.

Logistical constraints restrict the cost-effectiveness of distributing our
products from the UK, potentially limiting our penetration of the life sciences
research market outside of Europe. High quality commercial partners have been
identified in Asia and the Far East who will maintain a subset of our product
portfolio locally and distribute products regionally, with customers using a
local language GenomeCube module to identify, research and purchase products.

[buywell2] 20/3/2012 09:18

............................ Admirable Aspirations Methinks ..........................



Outlook

We are seeing growth across both divisions which is in line with the strategic plan implemented for the Group.

LifeSciences

We have forged a leading position in Europe for the provision of DNA sequencing services and genomic products. With our international network of facilities, we are ideally placed to meet the growing demand for ultra-fast sequencing analysis. Our share of the UK market for DNA sequencing has been boosted by the introduction of our Overnight Service and by the end of 2012 we aim to be the largest outsourced provider of DNA sequencing in the UK, a market worth an estimated £10 million per annum.

In addition, we have doubled capacity on the high throughput Illumina HiSeq 2000™ platform during the year and in combination with our conventional sequencing service, it is our short term aim to become Europe's leading sequencing provider.

The launch of GenomeCube® represented Phase II in the development of the commercial and operational infrastructure to drive sales of the product portfolio. The global market for clones and antibodies exceeds $1 billion and during 2012 Phase III of the GenomeCube® development will enable the Group to establish a network of distributors across Asia, representing an international expansion opportunity that has previously been limited.



Healthcare

The approval by the NHS of the BD FocalPoint™, our automated imaging system for cervical cancer screening, was an important trigger to further growth of our Cytology business. Demand is apparent from NHS Trusts across the UK looking to reduce laboratory costs and improve turnaround times for cervical screening.

In Diagnostics we are planning to take advantage of the increasing, but currently sub-optimal, demand by the NHS for outsourced services. With the UK government planning to reduce healthcare spending by £20 billion, the NHS is entering a period of considerable change and we believe this presents significant opportunities for our outsourcing model.
The global market for cancer diagnostics is estimated to be in excess of £4.0 billion and the market for molecular diagnostics is estimated at £1.5 billion and growing at 10% per annum. Our unique expertise in both these fields means that we are well placed to capitalise on the increasing demand for genetic testing and companion diagnostic testing for cancer and other diseases.
Patient stratification will become increasingly relevant and this will entail the use of genomic signatures for diagnostic and predictive purposes. The ability to provide many of the new and anticipated genetic tests is outside of the capability of all but a few NHS laboratories and is unlikely to be resourced in the near term. We see this as a significant opportunity to provide a broader diagnostic service to a wider customer base including infectious, cardiovascular and metabolic disease, in addition to oncology.


Conclusion
The Group's strategy is to grow its LifeSciences and Healthcare businesses both organically through its existing operations combined with appropriate investment, and by way of selected acquisitions to broaden the Group's portfolio of products and services, including expansion of our core expertise into complementary areas.

The Board remains confident that the opportunities for growth remain strong and we expect the markets for our services and products to improve. As described above, we are exploring new markets and will continue to exploit the cross-selling opportunities we now have from our broad customer base, enhanced portfolio and extended geographical reach. In order to match the demand for our services and products, we continue to equip the Group with the breadth and depth of service offering, technology platforms, expertise and products to deliver controlled growth and value to shareholders.

Dr Nick Ash
Chief Executive Officer
20 March 2012

[buywell2] 20/3/2012 09:03

*Results are stated after eliminating non-recurring restructuring costs of £0.6 million associated with the planned integration of the acquired imaGenes business and the impact of a charge of £2.8 million to reflect the fair value of the Head Office premises purchased during the year, as previously announced.


Hoped for a bit better , let´s see if the hoped for extra that did not materialise in 2011 carries over into 2012 results ..... I think it will

My guess it was PharmaBiotech work in 2011 that we missed out on due to others not getting patients sorted for trials

PharmaBiotech
As we have referred to previously, we have restructured elements of our commercial and operational infrastructure. As part of that restructuring, we have consolidated our PharmaBiotech commercial activities into our LifeSciences division. The aim of the consolidation is to identify and exploit opportunities to cross sell our expertise in genomics into our existing key pharma and biotech accounts where we already possess a strong relationship based on our clinical trials support and diagnostics services.
Interest in our "one stop shop" enhanced pathology to genomics offering is increasing from a broad range of pharma and biotech customers. We also expect to benefit from the significant changes in the pharma industry as it undergoes restructuring programmes requiring outsource partners and more cost effective and efficient ways to develop new drugs.
This new approach is already producing results and we have a pipeline of contracts for clinical trial support and genomic services worth in excess of £2.0 million between 2012 and 2015. However, as with any clinical trial support contract, the value to the Group depends on successful recruitment of patients onto a trial and, to some extent, the efficacy of the therapy being trialled, both of which are outside our control.

This is the sort of thing I expect to see repeated

Post-period event
• Access to FocalPoint™ is the determining factor in winning the University Hospital of North Staffordshire NHS Trust's liquid based cytology contract; this is the first Trust to switch liquid based cytology technology and is worth £0.3 million per annum

Hologic will be concerned

Will they be concerned enough to launch a bid ?

[garbil] 20/3/2012 08:00

Excellent figures in a tough economic environment:


Summary results

2011 2010 % change
£'000 £'000

Revenue 15,192 13,487 +13%

Gross profit 6,751 5,821 +16%

(Loss)/profit after tax (2,795) 93 -

Adjusted operating profit* 461 170 +171%

Adjusted profit after tax* 610 267 +128%

Adjusted EBITDA* 1,860 1,256 +48%

[wilkie_hk] 20/3/2012 07:20

Quite a lot to digest in these results. What would these average 'one off' restructure charges average out at over a number of years, as they seem to occur every other year? A previous release indicated that the EBITDA would benefit immediately by £0.5M from the purchase of the Nottingham premises, how does this affect the pre-tax? An evening job for me to look at as off to work now.

I suspect that there will be no significant movement in the share price today, and that there will be some time to review the results and make a judgement on whether the value is there to top up, buy in, hold or sell out.

[hastings] 20/3/2012 07:12

Solid enough paving the way for continued growth, should be interesting to see where the share price heads today!

[blondviking] 20/3/2012 07:10

Good set of results.

[buywell2] 16/3/2012 16:00

If that was right bert we might get an RNS soon

Mmmm looks like it was correct

[bert34] 16/3/2012 09:53

15:58:37 15-Mar-12 7.25 3,500,000 253,750.00

[hastings] 15/3/2012 20:53

Who knows!